Articles tagged with: Maintenance Therapy
Further findings from two clinical studies of Revlimid maintenance therapy were presented at the 14th International Myeloma Workshop (IMW) in Kyoto, Japan, earlier this month.
Both studies involved newly diagnosed multiple myeloma patients who received maintenance therapy with Revlimid (lenalidomide).
Results from both studies, which were published in the New England Journal of Medicine last May, indicate that Revlimid maintenance therapy significantly increases progression-free survival compared to a placebo (see related Beacon news). One of the studies also found that Revlimid maintenance therapy improved overall survival of patients. …
Looking back at all that has happened in the world of multiple myeloma since January of 2012, it is hard not to be impressed by the many important developments that took place.
There is the obvious fact that, during that time, not one, but two new drugs to treat myeloma were approved by the U.S. Food and Drug Administration (FDA). Prior to 2012, the FDA had not approved a novel anti-myeloma therapy in over six years.
Yet 2012 was meaningful to the myeloma community for reasons beyond the activity at …
Perhaps the title of this column more appropriately should be "Life After CRD," since I've now completed 24 cycles of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone (Decadron), commonly referred to as CRD, as part of a clinical trial for newly diagnosed patients.
However, since dexamethasone seemed to be the predominate source of my side effects, and because I liked the play on words, I went with the title as shown.
So, I've completed the clinical trial, I've reached stringent complete response, and I've won …
While I am not so much a creature of habit, my Wednesday afternoon activities over the last three years have been pretty much chiseled in stone.
At around noon on a typical Wednesday, I drop everything that I’m doing, jump into my car, drive across the Kimberling City Bridge that sits perched 30 feet above beautiful Table Rock Lake, and then wind my way through the rolling Ozark hills and picturesque hollows toward the nationally known tourist and entertainment small city of Branson, Missouri.
Upon arrival at my destination, I …
Results of a recent Spanish study suggest that elderly multiple myeloma patients who receive Velcade plus thalidomide or Velcade plus prednisone as maintenance therapy achieve deeper responses following initial therapy with Velcade-based treatment regimens.
In addition, elderly myeloma patients who receive Velcade plus thalidomide as maintenance therapy may achieve better treatment outcomes and longer survival rates than patients who receive Velcade plus prednisone as maintenance therapy.
“In our trial, VT [Velcade plus thalidomide] was slightly superior to VP [Velcade plus prednisone] in response rate and outcome, but the differences didn't …